Special Issue "Novel Anticancer Drug Delivery Systems"

A special issue of Pharmaceutics (ISSN 1999-4923).

Deadline for manuscript submissions: 31 October 2019

Special Issue Editors

Guest Editor
Prof. Sanjay Garg

School of Pharmacy and Medical Sciences, University of South Australia, Adelaide South Australia 5000, Australia
Website | E-Mail
Interests: controlled drug delivery; nanoparticles; targeted therapy; anticancer drug delivery systems; nanotechnology; antibacterials for superbugs; wound healing; veterinary formulations
Guest Editor
Assoc. Prof. Usha Y. Nayak

Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences (MCOPS), Manipal Academy of Higher Education, Manipal, Karnataka-576104, India
Website | E-Mail
Interests: controlled drug delivery; polymeric nanoparticles; liposomes; nanoemulsions; lipid nanoparticles; chronotherapeutics; solubility enhancement

Special Issue Information

Dear Colleagues,

Cancer is one of the leading causes of death worldwide, and there is a constant rise in cancer cases day by day. According to World Cancer Report, by the year 2020 there may be 15 million new cases of cancer. Currently, the cancer treatment strategies include surgery, chemotherapy, and radiotherapy, and it is widely known that these therapies inhibit the growth also of normal cells and are associated with high toxicity. The area of cancer therapy is a highly dynamic field, and breakthrough advancements are being made to develop novel strategies. Several strategies, such as receptor-based targeting, intracellular drug targeting, stimuli-based drug release, magnetic drug targeting, ultrasound-mediated drug delivery, gene delivery, and cancer stem cell therapy, have added new dimensions to the treatment approaches. These strategies aid in the selective detection and killing of tumour cells with minimal side effects and may be useful to reduce the chances of multidrug resistance, thus improving the quality of life of patients.

This Special Issue of Pharmaceutics focuses on "Novel Anticancer Drug Delivery Systems" which could help solve issues related to side effects, high toxicities, and drug resistance of anticancer drugs. Articles concerning all aspects of novel anticancer drug delivery systems, especially, new materials, strategies, and synthetic approaches are welcome for this Special Issue.

Prof. Dr. Sanjay Garg
Dr. Usha Y. Nayak
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer treatment
  • gene therapy
  • targeted therapy
  • stimuli-based release
  • stem cell therapy

Published Papers (2 papers)

View options order results:
result details:
Displaying articles 1-2
Export citation of selected articles as:

Research

Open AccessArticle
Short and Long-Term Effects of the Exposure of Breast Cancer Cell Lines to Different Ratios of Free or Co-Encapsulated Liposomal Paclitaxel and Doxorubicin
Pharmaceutics 2019, 11(4), 178; https://doi.org/10.3390/pharmaceutics11040178
Received: 10 March 2019 / Revised: 29 March 2019 / Accepted: 31 March 2019 / Published: 11 April 2019
PDF Full-text (11106 KB) | HTML Full-text | XML Full-text | Supplementary Files
Abstract
Background: Associating paclitaxel (PTX) to doxorubicin (DXR) is one of the main chemotherapy strategies for breast cancer (BC) management. Protocols currently available consist in administering both drugs on their maximum tolerated dose, not taking into account the possible differences in efficacy due to [...] Read more.
Background: Associating paclitaxel (PTX) to doxorubicin (DXR) is one of the main chemotherapy strategies for breast cancer (BC) management. Protocols currently available consist in administering both drugs on their maximum tolerated dose, not taking into account the possible differences in efficacy due to their combination ratio. In the present study, the short and long-term cytotoxic effects as well as migratory effects of PTX, DXR, and its combinations at 10:1; 1:1 and 1:10 PTX:DXR molar ratios either free or co-encapsulated in liposomes were evaluated against three human BC cell lines (MDA-MB-231, MCF-7, and SKBR-3). Method: The MTT assay was used to screen for synergy or antagonism between PTX and DXR and the combination index value was calculated using the CalcuSyn software. Nuclear morphological alterations were evaluated by staining the cells with Hoescht 33342. The investigation of senescence and clonogenicity of BC cell lines exposed to different treatments was also studied. In addition, the ability of these cells to migrate was assessed. Results: Taken together, the results presented herein allow us to suggest that there is no benefit in enhancing the PTX concentration above that of DXR in the combination for any of the three cell lines tested. Conclusion: The developed liposomes co-encapsulating PTX and DXR in different molar ratios retained the biological properties of the mixture of free drugs and are valuable for planning new therapeutic strategies. Full article
(This article belongs to the Special Issue Novel Anticancer Drug Delivery Systems)
Figures

Figure 1

Open AccessArticle
One-Pot Synthesis of Epirubicin-Capped Silver Nanoparticles and Their Anticancer Activity against Hep G2 Cells
Pharmaceutics 2019, 11(3), 123; https://doi.org/10.3390/pharmaceutics11030123
Received: 18 February 2019 / Revised: 11 March 2019 / Accepted: 12 March 2019 / Published: 15 March 2019
PDF Full-text (1334 KB) | HTML Full-text | XML Full-text
Abstract
Epirubicin-capped silver nanoparticles (NPs) were synthesized through a one-pot method by using epirubicin as both the functional drug and the reducing agent of Ag+ to Ag0. The preparation process was accomplished in 1 h. In addition, the obtained epirubicin-capped silver [...] Read more.
Epirubicin-capped silver nanoparticles (NPs) were synthesized through a one-pot method by using epirubicin as both the functional drug and the reducing agent of Ag+ to Ag0. The preparation process was accomplished in 1 h. In addition, the obtained epirubicin-capped silver nanoparticle was characterized by transmission electron microscopy (TEM), energy-dispersive X-ray spectroscopy (EDX), and infrared spectroscopy. The results showed that a layer of polymer epirubicin had formed around the silver nanoparticle, which was 30-40 nm in diameter. We further investigated the antitumor activity of the prepared epirubicin-capped silver nanoparticle, and the half maximal inhibitory concentration (IC50) against Hep G2 cells was 1.92 μg/mL, indicating a good antitumor property of the nanoparticle at low dosage. Full article
(This article belongs to the Special Issue Novel Anticancer Drug Delivery Systems)
Figures

Graphical abstract

Pharmaceutics EISSN 1999-4923 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top